Histologic Status of Squamous Cell Carcinoma In Situ After Diagnostic Biopsy in Immunocompetent and Immunosuppressed Patients

Abstract

Up to 16% of SCC-IS showed invasive SCC at the time of surgical treatment. Immunosuppressed patients are more likely to have residual disease after biopsy. IHC markers of invasive SCC may not predict invasion.

Revised Mohs surgery care guidelines for squamous cell carcinoma in-situ are overdue

“…Patients with certain hematologic malignancies, organ transplants, HIV, pharmacologic immunosuppression, and certain genodermatoses are at higher risk of developing SCC [28][29][30][31]. Moioli et al recently noted a non-significant, but higher percentage of residual SCCis or SCC in serially sectioned excision specimens of biopsy-proven SCCis from immunosuppressed patients [32]. The rate of complete tumor clearance after biopsy was significantly lower in immunosuppressed patients than in immunocompetent patients.…”